SCHEMBL20249456

SCHEMBL20249456

CC(C)(C)c1ccc(N2CCNC3(CC3)C2=O)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 3/20 0.36
CDK4 P11802 3/20 0.36
CDK1 P06493 1/20 0.36
LIPE Q05469 4/20 0.33
PIK3CD O00329 1/20 0.33
SIGMAR1 Q99720 1/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA4 P43681 1/20 0.32
ELANE P08246 1/20 0.31
OPRM1 P35372 2/20 0.31
KCNJ1 P48048 1/20 0.31
NR3C1 P04150 1/20 0.31
HSD11B1 P28845 2/20 0.31
DPP4 P27487 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31
CCNT1 O60563 1/20 0.31
CCND1 P24385 1/20 0.31
CCND3 P30281 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20249234 0.89 OPRL1 (0.34) OPRL1CDK4CDK1PIK3CDSIGMAR1
SCHEMBL20249323 0.88 CDK4 (0.42) OPRL1CDK4CDK1LIPESIGMAR1
SCHEMBL18291490 0.83 PIK3CD (0.36) OPRL1CDK4CDK1LIPEPIK3CD
SCHEMBL20037508 0.82 CDK4 (0.35) CDK4CDK1LIPEPIK3CDCHRNB2
SCHEMBL20249470 0.81 LIPE (0.40) CDK4LIPEEGLN1
SCHEMBL20249282 0.81 RAB9A (0.36) OPRL1CDK4CHRNB2CHRNA4ELANE
SCHEMBL20249255 0.80 CYP1A2 (0.41) OPRL1CDK4HSD11B1DPP4CCNT1
SCHEMBL20249254 0.76 HTR6 (0.40) CHRNB2CHRNA4
SCHEMBL25026927 0.75 CRBN (0.53) OPRL1
SCHEMBL20249225 0.75 SLC6A2 (0.45) OPRL1SIGMAR1NR3C1HSD11B1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 OPRL1 4655/4885CDK4 1/4885CDK1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.